NCT03945903No Longer Available不适用
SIMPONI SC Managed Access Program
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults. The main purpose of a single patient IND is to provide treatment to participants with serious/life-threatening diseases or conditions prior to marketing authorization.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT00488631Janssen Research & Development, LLC1,228
已完成
3 期
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)Arthritis, RheumatoidNCT00975130Merck Sharp & Dohme LLC3,366
招募中
2 期
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLCCarcinoma, Non-Small-Cell LungNCT05940532Hunan Cancer Hospital41
终止
2 期
Golimumab for the Treatment of Refractory Behcet's UveitisBehcet SyndromeUveitisNCT04218565Wenjie Zheng1
No Longer Available
不适用
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenSquamous Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung CancerNCT02475382Bristol-Myers Squibb